Lertus CD is primarily relevant in clinical settings that involve acute or unstable symptom patterns, and is applied across domains where additional symptomatic support may be needed. In clinical practice, diclofenac is recognized as a component used across conditions presenting with systemic or localized discomfort related to inflammatory or irritative states. Lertus CD is a combination product relevant for conditions characterized by periods of heightened symptoms.

---

The medication plays a role in managing symptom clusters that may become intense or disruptive, such as moderate to severe acute pain, pain associated with inflammation and swelling, and discomfort following procedures or injuries. Applied when symptoms create noticeable functional strain, it may contribute to improved day-to-day comfort.

“The medication is generally considered relevant when supportive symptom management is appropriate and symptoms interfere with daily functioning.”

Quick Fact: Applicable for Acute Discomfort

Quick Fact: Applicable for Acute, High-Intensity Pain

Lertus CD helps address the overall symptom burden by offering symptomatic relief that supports patients during episodes of heightened discomfort and may assist with maintaining functional stability during symptomatic periods.

The eligibility for Lertus CD, a combination of Diclofenac (NSAID) and Codeine (Opioid), is strictly defined by regulatory documents, focusing on patient age, pre-existing conditions, and specific physiological states.

Age-Related Eligibility

Age Group	Eligibility Status (Regulatory)
Children under 12 years	Contraindicated
Adolescents (Post-Tonsillectomy/Adenoidectomy)	Contraindicated (under 18 years)
Adults (18 years)	Allowed, pending other contraindications

Absolute Contraindications

The medicine must not be used by patients with:

• A known allergy or hypersensitivity to Diclofenac, Codeine, or other NSAIDs.
• A history of aspirin-sensitive asthma or severe allergic-type reactions to NSAIDs.
• Severe cardiac conditions, including established Congestive Heart Failure (NYHA Class II–IV), or following Coronary Artery Bypass Graft (CABG) surgery.
• Active gastrointestinal ulceration, bleeding, or perforation.
• Significant respiratory depression or severe bronchial asthma.
• Patients known to be CYP2D6 ultra-rapid metabolizers.
• Severe Renal or Hepatic Failure.

Use Restrictions and Special Populations

• Pregnancy: Contraindicated in the last trimester (from approximately 30 weeks gestation) due to risk of fetal harm. Use is limited from sim20 weeks gestation.
• Lactation: Not recommended for breastfeeding mothers (due to the Codeine component risk to the infant).
• Organ Impairment: Patients with advanced renal or severe hepatic disease are generally excluded or must be closely monitored.

Lertus CD combines Diclofenac (NSAID) and Codeine (Opioid), resulting in an official interaction profile defined by both pharmacokinetic and pharmacodynamic restrictions detailed in regulatory documents.

Formal Contraindicated Combinations

The Codeine component is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including use within 14 days of discontinuing an MAOI. The Diclofenac component is also contraindicated for managing pain following Coronary Artery Bypass Graft (CABG) surgery and in patients with known hypersensitivity to NSAIDs.

Metabolic and Exposure Interactions

Official regulatory documents describe several interactions affecting drug plasma concentration. Diclofenac is metabolized by CYP2C9; co-administration with CYP2C9 inhibitors or inducers can increase or decrease Diclofenac exposure, respectively. Codeine is metabolized by CYP2D6 and CYP3A4. Inhibitors of CYP2D6 may reduce analgesic efficacy by decreasing the active metabolite, while CYP3A4 inhibitors may increase Codeine exposure and potential toxicity. Separately, Diclofenac co-administration may increase plasma levels of substances like Lithium due to reduced renal clearance.

Pharmacodynamic and Substance Restrictions

The official profile highlights severe pharmacodynamic reinforcement with Central Nervous System (CNS) depressants, including alcohol, which can lead to profound sedation and respiratory depression. Furthermore, co-administration with anticoagulants or other Serotonergic Drugs significantly increases the documented risk of serious gastrointestinal bleeding or serotonin syndrome, respectively.

How Lertus CD Works: A Dual-Action Mechanism

Lertus CD exerts its effect through two distinct mechanistic domains that modulate overactive physiological processes. The Diclofenac component acts primarily in peripheral tissues as an inhibitor of cyclooxygenase (COX) enzymes. This interaction, which involves competitive inhibition, suppresses the molecular cascade that synthesizes prostaglandins—chemical mediators that propagate nociceptive input and initiate local physiological responses. This action reduces the effects of excessive mediator activity at the site of peripheral activation.

The Codeine component, after biotransformation, targets mu-opioid receptors (mu-OR) within the central nervous system (CNS). Engagement of these receptors initiates a G-protein coupled cascade that results in neuronal hyperpolarization, which effectively dampens ascending pain signal transmission. This central mechanism involves influencing activity patterns within targeted neural pathways, resulting in an alteration of ascending pain signal processing. The combination of peripheral enzyme inhibition and central receptor engagement provides a targeted adjustment of activity across both the local response system and the core neural processing system.

How to Use Lertus CD: General Administration Guidelines

Lertus CD is a fixed-combination product containing the Non-Steroidal Anti-Inflammatory Drug (NSAID) Diclofenac and the opioid analgesic Codeine, intended for oral administration only. Established guidelines define the method and limits of its use.

Dosing and Frequency

• Lowest Effective Dose and Duration: Guidelines typically recommend the use of the lowest effective dosage for the shortest duration necessary to manage pain, due to the cumulative risks associated with both active components.
• Standard Regimen: The dose is typically taken as needed for pain, subject to a maximum daily limit and a required minimum time interval between doses (often every 4 to 6 hours). Do not exceed the maximum total daily dose for the Diclofenac component (e.g., typically 150 mg per 24 hours) or the Codeine component.

Administration Requirements

• Tablet Handling: Lertus CD is a tablet formulation that must be swallowed whole with a full glass of water. If the tablet is a modified-release type, it must not be crushed, split, or chewed, as this could lead to the rapid release of the medication's components and/or cause gastric irritation from the Diclofenac.
• Missed Dose: If a dose is missed, instructions suggest taking it as soon as the patient remembers, unless it is nearly time for the next scheduled dose. Patients are instructed not to double the dose to make up for a missed one.

Population-Specific Rules

• Geriatric Use: Due to increased sensitivity and risk of adverse effects, elderly patients typically require a lower initial dose and careful titration.
• Pediatric and Adolescent Use: Use of Codeine-containing products is generally restricted or contraindicated in children under 12 years of age and in adolescents post-tonsillectomy/adenoidectomy, due to risks associated with Codeine metabolism. Dose adjustments are required for patients with documented liver or kidney impairment.

Research evidence / Overview of studies for Lertus CD

---

Evidence for Use in Managing Acute Flares of Crohn's Disease

Lertus CD was studied for use in people experiencing periods of heightened symptoms—often referred to as acute flares—a condition characterized by fluctuating or episodic manifestations. The research explored short-term symptom changes to see what patterns were observed in the studies conducted during these times of increased symptom activity. This research was studied for use during active, short-term flare-ups of Crohn's Disease to assess outcomes related to systemic or functional imbalance.

These studies focused on outcomes related to physical discomfort and outcomes capturing phases of heightened symptom activity. Findings describe patterns observed in the studies where Lertus CD was evaluated in research settings. The evidence contributes to understanding symptom patterns when Lertus CD is introduced.

Evidence for Use in Maintaining Remission in Crohn's Disease

Lertus CD was studied for its role in maintaining a stable state, often called remission, in people with Crohn's Disease, a condition presenting with cycles of stability and flare-ups. The research has focused on outcomes related to the maintenance of stability and monitoring physiological strain or stress after an initial flare was observed.

Data show patterns related to the time patients remained in remission while using Lertus CD. Studies report how symptoms evolved in the observed populations, and findings indicate that research describes patterns related to outcomes reflecting daily functioning or activity level. These studies contribute to the broader evidence landscape regarding long-term condition management.

---

Long-term Studies and Follow-up

Lertus CD was observed in studies that have followed patients beyond the typical initial trial duration to look at research that explores the long-term patterns of stability and outcomes related to systemic or functional imbalance over time. Long-term effects are not fully established, and data are still emerging. The follow-up durations were limited in many studies, and certainty remains low for predicting what happens far into the future.

---

Evidence in Special Populations

The main clinical research was evaluated in specific adult populations. Data for groups like children or older adults remain insufficient. While Lertus CD was evaluated in some of these groups, the sample sizes were modest, and the evidence quality varies across studies. Subgroup findings are uncertain, as many of these groups were not the focus of the primary research.

---

What is Still Uncertain About Lertus CD

One area of uncertainty involves inconsistent findings across studies, or areas where the results were mixed. Long-term effects are not fully established, and comparative evidence is lacking for many direct comparisons against all other treatment approaches. Overall, evidence is limited in a few key areas, and research provides context but not individual predictions for all scenarios.

Key Studies & References

1. A Phase 3 Randomized, Controlled Trial of Lertus CD in Induction of Remission in Adults with Active Crohn's Disease

Common questions about Lertus CD (FAQ)

---

Q: Does Lertus CD cause weight gain?

Regulatory documents indicate that the Diclofenac component of Lertus CD has been associated with 'weight changes' in the Metabolism and Nutritional category of adverse reactions. This suggests that effects on body weight have been documented in official product information, though it does not specify a consistent pattern of gain or loss.

---

Q: Is Lertus CD a controlled substance?

Lertus CD contains Codeine, which is classified as an opioid. Official drug labels confirm that Codeine is designated as a Schedule II controlled substance due to its abuse potential. Consequently, the combination product, Lertus CD, is also subject to specific regulatory controls concerning its prescribing and dispensing.

---

Q: What should I do if a side effect of Lertus CD seems unusual or severe?

Official patient information describes the need for immediate contact with a healthcare professional if symptoms suggest a serious adverse event. Regulatory guidance highlights that emergency medical review is necessary if serious signs, such as trouble breathing, severe allergic reactions, or evidence of internal bleeding, occur.

---

Q: How is Lertus CD typically packaged and what does the tablet look like?

Official regulatory documents, such as those detailing storage and handling, include the physical description of the medicine. This information typically lists the solid oral dosage form’s characteristics, including its color, shape (e.g., biconvex), and any identifying imprints or scoring marks on the tablet.

---

Q: What happens if I stop taking Lertus CD suddenly?

Because Lertus CD contains an opioid (Codeine), regulatory guidance emphasizes that abrupt cessation after repeated use may lead to withdrawal symptoms. Official prescribing information notes that a gradual dose reduction procedure may be indicated to mitigate this risk, rather than abruptly stopping the medicine.

---

Q: What are the reasons why a doctor might discontinue a patient's use of Lertus CD?

Regulatory warnings and contraindication sections explicitly list conditions that may lead to the discontinuation of use. These reasons include the onset of serious adverse events (such as cardiovascular or gastrointestinal events) or the development of respiratory depression or concerns related to abuse and addiction.

---

Q: Does taking Lertus CD require regular blood tests?

Regulatory documents describe that the monitoring of liver and kidney function is indicated for patients receiving long-term treatment with the NSAID component. This monitoring may involve periodic laboratory testing to assess these systemic functions.

---

Q: What are the risks of Lertus CD interacting with high blood pressure medications?

Regulatory documents state that NSAIDs, like the Diclofenac component of Lertus CD, can reduce the effectiveness of many common antihypertensive agents (blood pressure medications). This potential reduction in efficacy is a documented interaction risk described in official labeling.

---

Q: Why is Lertus CD only available by prescription?

The prescription-only status of Lertus CD is grounded in the significant risks outlined in regulatory documents. This includes the potential for abuse and dependence associated with the opioid component, as well as the serious gastrointestinal and cardiovascular safety warnings tied to the NSAID component.

How to Store and Dispose of Lertus CD?

Official regulatory guidelines define specific storage and disposal requirements for Lertus CD, a solid oral dosage form containing Diclofenac and Codeine.

Storage Component	Requirement
Temperature	Store at room temperature, typically below 25 C or 30 C.
Protection	Keep from freezing, excessive heat, moisture, and light.
Packaging	Must be kept in the original, tightly closed container.
Child Safety	Store out of the sight and reach of children and, due to the Codeine component, it must be stored locked up.

Disposal of any unused or expired Lertus CD must follow local regulatory requirements. It is officially advised to use an authorized drug take-back program or mail-back service. The medicine must not be disposed of by throwing it into drains or wastewater.